Oncolix Inc. (fka ONCX)

[Rat Fink]

M.D. ANDERSON'S PRE-CLINCAL TRIAL "ONCOLIX" PROLANTA (G129R) http://nebula.wsimg.com/5542c0afba149bcb25b0b56a5099a065?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

Conclusion (lower left-hand corner): G129R functions as a molecular
antagonist to tumor-associated PRL by inducing
adaptive autophagic cell death in human ovarian cancer.
These preclinical findings reveal the novelty of G129R as
an adjuvant therapy for ovarian cancer

CONCLUSIONS (LOWER RIGHT-HAND CORNER)
1. Prolactin antagonist, G129R, inhibits ovarian cancer growth and
progression;
2. PRLR is required for G129R induced autophagy;
3. PEA-15 mediates autophagic cell death induced by blocking
PLR/PRLR signaling;

Prolanta™ (referenced in the scientific literature as G129R): https://www.oncolixbio.com/prolanta-structure.html

Prolanta: https://www.oncolixbio.com/home.html


o PRIVATE COMPANY "ONCOLIX" RECENTLY PURCHASED PUBLIC SHELL COMPANY "AEPP".

o "ONCOLIX" HAS 8 PATENTS IN U.S. AND PATENTS IN OTHER COUNTRIES.

o ALL "AEPP" DEBT WAS PAID OFF BY "ONCOLIX" AT PURCHASE.

o "AEPP" HAS A LOW FLOAT: 33,311,633 a/o Apr 06, 2017 PER OTCMARKETS.COM: https://www.otcmarkets.com/stock/AEPP/profile

o "ONCOLIX" HAS ORPHAN DRUG "PROLANTA" CURRENTLY IN FDA-APPROVED PHASE 1 TRIALS.

o INVENTOR OF "PROLANTA" ALSO INVENTED "SOMAVERT" SOLD BY PFIZER. "SOMAVERT" YIELDED $232M IN REVS LAST YEAR.

o BRAND NEW "ONCOLIX" WEBSITE: https://www.oncolixbio.com/home.html

o APRIL 2017 "ONCOLIX" COMPANY PRESENTATION: https://nebula.wsimg.com/8b544fcbb6f5bf5fb52c1c7e5a69eb81?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1